Androgenetic alopecia

Patients should be followed by a dermatologist to monitor efficacy of therapy.
There are no laboratory tests indicated in men who are using topical minoxidil or finasteride.
For safety purposes, women taking spironolactone should have potassium levels checked prior to therapy. Monitoring potassium levels may not be necessary unless patients have cardiac or renal dysfunction, or are on other medications that could lead to hyperkalaemia.[59][60]
Women with concomitant hyperandrogenism who are treated with antiandrogens or are on oral contraceptives must have levels of free testosterone and dehydroepiandrosterone (DHEA)-sulfate measured 3 to 4 months after onset of therapy.
There is a cumulative dose-dependent association between cyproterone acetate and meningioma. Clinicians should be vigilant for signs and symptoms of meningioma in patients prescribed cyproterone acetate (especially if at higher doses) for long periods of time.[61][62]

Use of this content is subject to our disclaimer

Monitoring